KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to -$278.2 million.

  • Alnylam Pharmaceuticals' Consolidated Net Income rose 325.05% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 113.11%. This contributed to the annual value of -$278.2 million for FY2024, which is 36.82% up from last year.
  • Alnylam Pharmaceuticals' Consolidated Net Income amounted to -$278.2 million in FY2024, which was up 36.82% from -$440.2 million recorded in FY2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Consolidated Net Income peaked at -$278.2 million during FY2024, and registered a low of -$1.1 billion during FY2022.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Consolidated Net Income value was -$440.2 million (recorded in 2023), while the average stood at -$616.5 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Consolidated Net Income tumbled by 32.64% in 2022, and later spiked by 61.08% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Consolidated Net Income (Yearly) stood at -$858.3 million in 2020, then climbed by 0.64% to -$852.8 million in 2021, then tumbled by 32.64% to -$1.1 billion in 2022, then spiked by 61.08% to -$440.2 million in 2023, then soared by 36.82% to -$278.2 million in 2024.